FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing fibroblast-based therapies for patients with chronic diseases that have significant unmet medical needs. The firm's core activity revolves around its fibroblast technology platform, which utilizes human dermal fibroblasts to create allogeneic cell therapies designed to promote tissue regeneration and modulate immune responses. Its most advanced product candidates include CYWC628 for wound healing, CYMS101 for multiple sclerosis, CybroCell™ for degenerative disc disease, and CYPS317 for psoriasis, with earlier stage programs exploring thymic involution reversal and anticancer organoid applications. The firm’s scientific foundation rests on preclinical work that demonstrated fibroblast capabilities in tissue repair, immune modulation, and chondrogenic differentiation under mechanical stimuli. The company was formed in April 2021 as a Texas limited liability company, converted to a Delaware corporation in December 2021, and renamed to its current form in April 2023.
As of the date of the filing, FibroBiologics, Inc. has not reported any product revenue and depends on external funding to sustain its operations. The company has issued Series A Preferred Stock to its former parent, SpinalCyte LLC, and continues to raise capital through private placements and potential future public offerings. Proceeds from these financing efforts have been applied to secure contract manufacturing organization services, to conduct IND enabling studies, and to maintain the corporate infrastructure required for a clinical stage biotech. These financing activities support research and development, preclinical studies, clinical trial execution, and the manufacture of clinical material for its product candidates.
FibroBiologics, Inc. positions itself as a specialized participant in the regenerative medicine arena, promoting fibroblast cells as a distinct alternative to mesenchymal stem cell platforms. In the wound healing market, its lead candidate CYWC628 competes with existing products such as Apligraf, Grafix, DermACELL, and TheraSkin, which are derived from neonatal cells or placental membranes. For multiple sclerosis, CYMS101 would contend with approved disease modifying therapies from companies including Biogen, Roche, Novartis, Johnson & Johnson, and TG Therapeutics. In degenerative disc disease, CybroCell™ faces competition from entities such as Mesoblast Limited, Aesculap Implant Systems, Novartis, Pfizer, Eli Lilly, DiscGenics, Spine BioPharma, and Ferring B. V., which offer surgical devices, biologics, or cell based therapies. The psoriasis candidate CYPS317 would be measured against biologics from Amgen, Johnson & Johnson, AbbVie, and Eli Lilly, as well as emerging cell based approaches. The company highlights several competitive advantages derived from its fibroblast platform: fibroblasts can be obtained noninvasively from skin donors obtained during routine procedures such as abdominoplasty, they proliferate faster in culture than stem cells, they exhibit stronger immunomodulatory activity, they are already differentiated and therefore do not risk spontaneous differentiation, and they produce higher levels of regenerative cytokines and growth factors while requiring less expensive culture media. These characteristics are intended to lower manufacturing costs, improve scalability, and enhance therapeutic potency relative to stem cell based alternatives. The firm also points to the broad applicability of fibroblast cells across multiple therapeutic areas as a strategic advantage that reduces reliance on a single indication.
The company intends to serve patients who suffer from chronic wounds such as diabetic foot ulcers, individuals with relapsing or progressive forms of multiple sclerosis, patients experiencing degenerative disc disease and associated back pain, and those affected by moderate to severe psoriasis. Healthcare providers that would administer these future therapies include hospitals, wound care clinics, neurology centers, spinal surgery facilities, and dermatology practices. Although the filing does not disclose specific customer names, the target market consists of both public and private healthcare institutions that seek advanced regenerative treatment options. The company anticipates that successful products will seek coverage from Medicare, Medicaid, and private insurers once clinical efficacy and safety are established.